Agile Sciences has been awarded $1,030,000 from the National Institutes of Health (NIH) to advance preclinical development of the company's novel antibiofilm treatment for dental caries.
The Phase II Small Business Innovation Research Award follows a $252,000 Phase I SBIR award granted to Agile Sciences in August 2010.
Agile Sciences has developed proprietary compounds that are able to inhibit the formation of oral biofilms and disperse existing biofilms, according to a company press release. The new funding will enable the company to evaluate the efficacy and safety of these compounds.
Agile Sciences' Phase II project will begin immediately and continue for two years.
